Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Erlotinib

3

XXI.e Rechallenge may not necessarily lead to relapse of AE/ILD

1
Last update : 04/01/2020
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Tyrosine kinase inhibitors (EGFR) TKI
5

Publications

Erlotinib-associated interstitial pneumonitis with successful readministration.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2024 Jan;30;206-209 2024 Jan
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Jun;6;1142-3 2011 Jun

Powered by

  • ^
  • Contact
  • Cookies
  • About